SHOW ME THE DATA®

HOW THE EXPERTS MAKE EVIDENCE-BASED TREATMENT DECISIONS IN PROSTATE CANCER

VIRTUAL SATELLITE SYMPOSIUM

WEDNESDAY, JUNE 16, 2021
7:00 PM - 9:00 PM EDT

PROGRAM CHAIR
Alicia K. Morgans, MD, MPH

For more information, visit us at...
gotoPER.com

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #goptoper.
Dear Colleague:

On behalf of Physicians’ Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Show Me the Data®: How the Experts Make Evidence-Based Treatment Decisions in Prostate Cancer**.

This PER® Show Me the Data® activity features a panel of experts who will discuss the latest clinical trial findings and guideline recommendations for patients with prostate cancer. Using patient case examples, these experts will present the most recent evidence for developing a comprehensive medical approach for these patients, and what this approach looks like in clinical practice.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with prostate cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let’s work together to make this an educational experience that will make a positive difference for our patients.

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

**Alicia K. Morgans, MD, MPH**  
Associate Professor of Medicine  
Feinberg School of Medicine  
Northwestern University  
Chicago, IL  

**Phil Talamo, CHCP**  
President  
Physicians’ Education Resource®, LLC  
Cranbury, NJ  
ptalamo@gotoper.com
### Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PM</td>
<td>Welcome and Introductions</td>
<td>Alicia K. Morgans, MD, MPH</td>
</tr>
<tr>
<td>7:05 PM</td>
<td>Diagnostics and Treatment Guidelines: Setting the Stage for Care</td>
<td>Ashley E. Ross, MD, PhD</td>
</tr>
<tr>
<td>7:20 PM</td>
<td>Key Clinical Updates and Ongoing Trials in Prostate Cancer</td>
<td>Oliver Sartor, MD</td>
</tr>
<tr>
<td>7:35 PM</td>
<td>Show Me the Data® Case 1: Guideline-Based Recommendations With High-Volume mHSPC</td>
<td>Alicia K. Morgans, MD, MPH</td>
</tr>
<tr>
<td>7:55 PM</td>
<td>Show Me the Data® Case 2: Optimizing Management of Nonmetastatic CRPC</td>
<td>Ashley E. Ross, MD, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Oliver Sartor, MD</td>
</tr>
<tr>
<td>8:25 PM</td>
<td>Show Me the Data® Case 3: Sequencing Therapy in mCRPC</td>
<td>Himisha Beltran, MD</td>
</tr>
<tr>
<td>8:45 PM</td>
<td>Wrap-Up, Postassessment Questions, and Q&amp;A</td>
<td>All Faculty</td>
</tr>
<tr>
<td>9:00 PM</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

### Upcoming PER® Conferences

**2021**

- **5th Annual International Congress on Oncology & Pathology™**: Towards Harmonization of Pathology and Oncology Standards - Virtual Conference  
  - Saturday, June 26
- **5th Annual Live Medical Crossfire®**: Hematologic Malignancies - Virtual Conference  
  - Saturday, July 17
- **20th Annual International Congress on the Future of Breast Cancer® East - Hybrid Meeting**  
  - July 17-18
- **22nd Annual International Lung Cancer Congress® - Hybrid Meeting**  
  - July 29 - August 1
- **20th Annual International Congress on the Future of Breast Cancer® West - Hybrid Meeting**  
  - July 30 - August 1
- **5th Annual School of Nursing Oncology™ - Virtual Conference**  
  - August 6 - 7
- **18th Annual Annual Meeting of the International Society of Gastrointestinal Oncology® - Hybrid Meeting**  
  - October 1-2
- **19th Annual School of Breast Oncology® - Hybrid Meeting**  
  - October 28 - 30
- **39th Annual CFS®: Innovative Cancer Therapy for Tomorrow - Hybrid Meeting**  
  - November 3-5
- **16th Annual New York Lung Cancers Symposium® - Hybrid Meeting**  
  - Saturday, November 6
- **6th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application**  
  - Saturday, December 11

**2022**

- **18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®**  
  - Saturday, February 5
- **26th Annual International Congress on Hematologic Malignancies®**  
  - February 24-27
- **39th Annual Miami Breast Cancer Conference®**  
  - March 3-6
- **5th Annual School of Gastrointestinal Oncology®**  
  - Saturday, March 26
Target Audience
This educational program is directed toward medical oncologists, surgical oncologists, urologists, and radiation oncologists who treat prostate cancer. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with prostate cancer are also invited to attend.

Learning Objectives
At the conclusion of this activity, you should be better prepared to:

• Evaluate recently reported clinical trial data likely to impact prostate cancer care in the near future
• Integrate clinical trial data, real-world evidence, and expert opinion to apply optimal personalized care for patients with prostate cancer
• Identify strategies to monitor and manage adverse events associated with systemic therapy for prostate cancer
• Apply biomarker testing strategies in diagnosis and treatment monitoring across lines of care in prostate cancer

Slides/e-Syllabus
Final slides will be uploaded to the e-syllabus on the PER® website by 12:00 PM Eastern Time on Thursday, June 17, 2021. To access these materials, please visit https://www.gotoper.com/go/june21prostate.

How to Request Credit
To complete the online evaluation and receive a certificate of credit or participation, please visit https://education.gotoper.com/activity/june21prostate.

The online evaluation and request for credit will be available immediately following the program and will remain available until September 16, 2021.

Accreditation/Designation of Credit
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Thank you for attending How The Experts Make Evidence-Based Treatment Decisions in Prostate Cancer
To register for upcoming accredited CE live activity or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER® accredited CE activities.
Disclosures and Conflict of Interest (COI) Mitigation

Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians’ Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Grant/Research Support</th>
<th>Consultant</th>
<th>Speakers’ Bureau</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alicia K. Morgans, MD, MPH</td>
<td>Bayer Healthcare, Sanofi, Seattle Genetics, Dendreon, Astellas Pharma</td>
<td>Astellas Pharma, Sanofi, Bayer Healthcare, Dendreon, Glovis Oncology, Myovant Sciences, AstraZeneca, Janssen Pharmaceuticals, AAA, Exelixis, Pfizer, Blue Earth Diagnostics, Novartis Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Himisha Beltran, MD</td>
<td>Janssen Pharmaceuticalis, AbbVie/Stemcentrx, Bristol Myers Squibb</td>
<td>Janssen Pharmaceuticalis, AstraZeneca, Merck &amp; Co, Pfizer, Foundation Medicine, Blue Earth Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Ashley E. Ross, MD, PhD</td>
<td>Bayer Healthcare, Sanofi, Seattle Genetics</td>
<td>Astellas Pharma, Sanofi, Bayer healthcare, Dendreon, Glovis Oncology, Myovant Sciences, AstraZeneca, Janssen Pharmaceuticals</td>
<td>Janssen Pharmaceuticalis, GenomeDx, Myovant Sciences, Bayer Healthcare, Tempus</td>
</tr>
<tr>
<td>Oliver Sartor, MD</td>
<td>Advanced Accelerator Applications, AstraZeneca, Bayer Healthcare, Constellation Pharma, Dendreon, Endocyte, Invitae, Janssen Pharmaceuticalis, Merck &amp; Co, Progenesis Pharmaceuticals, Sanofi, SOTIO</td>
<td>Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer Healthcare, Blue Earth Diagnostics, Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Glovis Oncology, Constellation Pharma, Dendreon, EMD Serono, Fusion Pharmaceuticals, Isotopen Technologien Muenchen, Janssen Pharmaceuticalis, Myovant Sciences, Myriad Genetics, Noria Therapeutics, Novartis Pharmaceuticalis, Noxopharm, Progenesis Pharmaceuticals, POINT Biopharma, Pfizer, Sanofi, TeneoBio, Telix Pharmaceuticals, Theragnostics</td>
<td></td>
</tr>
</tbody>
</table>

*Information accurate at time of posting

PER® has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer
This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Faculty

Program Chair

Alicia K. Morgans, MD, MPH
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Alicia K. Morgans, MD, MPH, is an associate professor of medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She specializes in investigating complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship. She also studies the way patients and their care teams make treatment decision-making for metastatic prostate cancer. She has been awarded several Prostate Cancer Foundation grants to investigate the cognitive effects and quality of life effects of hormonal treatments in advanced prostate cancer, and a Department of Defense grant to assess treatment decision-making. She serves on the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and is a member of the cardio-oncology committee of American Heart Association. She also acts as the principal investigator for the ERADICATE phase 3 adjuvant trial for men with localized prostate cancer, and has a leadership role in several other ECOG and NRG trials. In addition, she is the president of the Medical Advisory Board and the vice chair of the Board of Directors of ZERO, a prostate cancer advocacy organization, and serves as the principal investigator for multiple therapeutic and noninterventional prostate cancer and bladder cancer clinical trials at Northwestern University.

Faculty

Himisha Beltran, MD
Medical Oncologist & Physician Scientist
Associate Professor of Medicine
Department of Medical Oncology
Lank Division of Genitourinary Oncology and the Division of Molecular and Cellular Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Himisha Beltran, MD, is an associate professor of medicine and director of translational research in the Department of Medical Oncology at the Dana-Farber Cancer Institute/Harvard Medical School. Her clinical and laboratory research focuses on understanding mechanisms of treatment resistance in advanced prostate cancer and the development of biomarker-driven therapeutic strategies. She leads clinical trials and team science projects that integrate multiple disciplines in order to accelerate translational research.
Faculty

Ashley E. Ross, MD, PhD
Associate Professor of Urology
Feinberg School of Medicine
Northwestern University
Chicago, IL

Ashley E. Ross, MD, PhD, is an associate professor of urology at the Northwestern Feinberg School of Medicine in Chicago, Illinois. His research and clinical efforts focus on the development, testing and implementation of novel diagnostics and therapeutics, with a goal of reducing the suffering from prostate cancer. Prior to joining the Feinberg School of Medicine, Dr. Ross served as director of the Johns Hopkins Urology Prostate Cancer Program, the executive medical director of the Mary Crowley Cancer Research Center, and an associate chair of the US Oncology Genitourinary Research Committee.

Oliver Sartor, MD
C.E. & Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, LA

Oliver Sartor, MD, is the C.E. and Bernadine Laborde professor of cancer research and medical director of the Tulane Cancer Center in New Orleans, Louisiana. His clinical and research interests focus on prostate cancer, and he is involved in a variety of clinical trials on translational issues and advanced treatments. Dr Sartor has published over 400 peer-reviewed manuscripts and has been an invited lecturer in 33 countries throughout his career. He has been the principal investigator (PI) and co-PI on 4 pivotal trials leading to FDA approvals (Quadramet, Jevtana, Eligard, and Xofigo). He serves widely as a consultant to biotechnology companies on matters pertaining to prostate cancer and drug development projects, particularly on matters pertaining to radiopharmaceuticals.
In 10-15 minute increments over the course of a few days, I can be caught up with the most relevant up to the minute standards in clinical oncology.

- 2020 Attendee

For more information, visit us at gotoper.com/go/CFS21